Delivery Order SPE2DB24D2018-SPE2DB25FWWH1
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $19,059.32 firm fixed-price delivery order on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This is a non-set-aside competitive award with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $17,506.81 on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectable medication, with final completion scheduled for August 21, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency (DLA) awarded a $14,874.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 20, 2025, with an ultimate completion date of August 21, 2025. This non-competitive delivery order was fulfilled from AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle extending through December 2026. The product...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,827.73 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 19, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,155.01 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 13, 2025, with completion scheduled for August 14, 2025. This non-competitive, firm fixed-price delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors with a ceiling value of $16,361.85. This firm fixed-price contract, which expires August 21, 2025, represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procedures with no set-aside designation, and performance...
- The Defense Logistics Agency awarded a $14,455.29 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is AmerisourceBergen's...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWH1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,143.16 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's larger indefinite delivery/indefinite quantity (IDIQ) master agreement with DLA Troop Support Medical (SPE2DX), a $999.9 billion pharmaceutical prime vendor contract valued through December 2026 that enables the company to supply a comprehensive range of medications and medical supplies to support military healthcare systems globally. AmerisourceBergen Drug Corp, one of the nation's major pharmaceutical distributors, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver diverse pharmaceutical products ranging from specialty medications to vaccines and medical devices. This award for Zepbound, a diabetes treatment medication, reflects AmerisourceBergen's ongoing role as a primary supplier within DLA's Medical Supply Chain and supports the Department of Defense's pharmaceutical procurement objectives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.1k | 8/18/25 |